Cerebellar toxicity during cytarabine therapy associated with renal insufficiency.
Acute cerebellar toxicity with ataxia and dysarthria is a well-known side effect during high-dose cytarabine therapy. Dose, age, previous neurological disorders, hepatic dysfunction, and renal insufficiency have been inconsistently reported as risk factors. The present paper presents a patient with renal insufficiency who developed severe cerebellar toxicity following treatment with a dose of cytarabine (8 g/m2 over 5 days) not generally expected to be associated with neurotoxicity. Together with a review of the literature, the present case gives evidence of renal insufficiency as a major risk factor in the development of cerebellar toxicity during cytarabine therapy. Reduced doses of cytarabine should be considered in patients with renal impairment.
Hasle
H
H
Department of Oncology and Radiotherapy, University Hospital of Odense, Denmark.
D058186:Acute Kidney Injury / Q000139:chemically induced*; D000368:Aged; D002526:Cerebellar Diseases / Q000139:chemically induced* / Q000209:etiology; D003561:Cytarabine / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D012307:Risk Factors
D003561:Cytarabine